放射免疫治疗中的α核素微剂量研究

田源; 张良安

放射免疫治疗中的α核素微剂量研究

田源 , 张良安

文章导航 > 国际放射医学核医学杂志 > 2006, 30 > 1: (39-41)

引用本文:

Citation:

放射免疫治疗中的α核素微剂量研究

田源,
张良安

300192 天津, 中国医学科学院中国协和医科大学放射医学研究所保健物理研究室
中图分类号: R144.1

A review of microdosimetric study in alpha particle radioimmunotherapy

Department of Health Physics, Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300192, China
CLC number: R144.1

摘要: 微剂量研究在临床α核素放免治疗的计划设计和疗效评价中起重要作用。设计一整套既能准确描述α粒子在细胞、亚细胞水平上剂量的不均匀分布,又适于临床使用的微剂量估算模型,一直是该领域的重要研究内容。本文介绍了α核素微剂量计算的几种常用方法以及最新发现的显著影响其结果精确度的因素。
- α粒子 /
- 放射免疫治疗 /
- 微剂量
Abstract: Microdosimetry plays an important role in the clinical application of alpha-particle radioimmunotherapy. There is increasing interest to develop a set of microdosimetric model, which can exactly describe the nonuniformly distribution of dose at cellular or sub-cellular level as well as can be conveniently used in clinic. In this paper, introduce some common methods of microdosimetry and some important affective factors reported in current researches on alpha-particle radioimmunotherapy.
- α-Particle /
- Radioimmunotherapy /
- Microdosimetry
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Goddu SM,Howell RW,Bouchet LG,et al.MIRD cellular s values:self-Absorbed dose per unit cumulated activity for selected radionuclides and monoenergetic electron and alpha particle emitters incorporated into,850 samuel morse drive,reston,VA20190-5136:Society of Nuclear Medicine,1997
[2]	Wilson WE,Nikjoo H.A monte carlo code for positive ion track simulation.Radiat Environ Biophys,1999,38(2):97-104.
[3]	Aubineau-Laniece I,Pihet P,Winkler R,et al.Monte carlo code for microdosimetry of inhaled alpha emitters.Radiat Prot Dosimetry,2002,99(1-4):463-468.
[4]	Stewart RD,Wilson WE,Mcdonald JC,et al.Microdosimetric properities of ionizing electrons in water:a test of the PENELOPE code system.Phys Med Biol,2002,47(1):79-88.
[5]	Tung CJ,Liu CS,Wang JP,et al.Calculation of cellular microdosimetry parameters for alpha particles and electrons.Appl Radiat Isot,2004,61(5):739-743.
[6]	Roeske JC,Stinchcomb TG.Tumor control probability model for alphaparticle-emitting radionuclides.Radiat Res,2000,153(1):16-22.
[7]	Kvinnsland Y,Stokke T,Aurlien E.Radioimmunotherapy with alpha-particle emitters:microdosimetry of cells with a heterogeneous antigen expression and with various diameters of cells and nuclei.Radiat Res,2001,155(2):288-296.
[8]	Palm S,Humm JL,Rundqvist R,et al.Microdosimetry of astatine-211 single-cell irradiation:role of daughter polonium-211 diffusion.Med Phys,2004,31(2):218-225.
[9]	ICRP.Limits for Intakes of Radionuclides by workers.International Com-mission on Radiological Protection,Pubilication 30.Oxford,UK:Pergamon,1979.
[10]	Bolch WE.α-particle emitters in radioimmunotherapy:new and welcome challenges to medical internal dosimetry.J Nucl Med,2001,42(8):1222-1224.
[11]	Ünak T.Some microdosimetrc data on Astatine-211.Appl Radiat Isot,2003,58(1):115-117.

[1]	吴凡 , 李林法 , 易贺庆 . α粒子放射性药物在骨转移瘤治疗中的应用进展. 国际放射医学核医学杂志, 2022, 46(2): 112-115. doi: 10.3760/cma.j.cn121381-202106027-00134
[2]	王丽琴 , 屈喜梅 , 焦玲 , 丁艳秋 , 武权 , 张文艺 . 水中总α、β放射性测量概述. 国际放射医学核医学杂志, 2012, 36(3): 164-167. doi: 10.3760/cma.j.issn.1673-4114.2012.03.011
[3]	袁志斌 . Zevalin^TM:一种放射免疫治疗新药. 国际放射医学核医学杂志, 2002, 26(5): 225-227.
[4]	李敏杰 . 胰腺癌的放射免疫治疗进展. 国际放射医学核医学杂志, 2003, 27(4): 154-156.
[5]	田嘉禾 . 关于放射免疫治疗的新思考. 国际放射医学核医学杂志, 1997, 21(z1): 249-252.
[6]	高云朝 . 恶性胶质瘤的放射免疫治疗. 国际放射医学核医学杂志, 2004, 28(4): 149-152.
[7]	仲恒高 , 童建 . α粒子辐射与基因组不稳定性. 国际放射医学核医学杂志, 2004, 28(6): 267-270.
[8]	任均田 , 林学颜 . 放射免疫显像与治疗的应用进展. 国际放射医学核医学杂志, 1995, 19(2): 57-59.
[9]	杨卫东 , 汪静 . 肿瘤核素靶向治疗新进展. 国际放射医学核医学杂志, 2015, 39(1): 19-24, 36. doi: 10.3760/cma.j.issn.1673-4114.2015.01.006
[10]	崔瑞雪 , 卢倜章 . ⁹⁰Y在肿瘤治疗中的应用. 国际放射医学核医学杂志, 1996, 20(5): 208-211.